Back to Newsroom

Oncobiologics Announces Presentation Of Final Data From Phase 1 Clinical Study Of ONS-3010 (HUMIRA® Biosimilar)

CRANBURY, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today presented final data from the Phase 1 trial evaluating bioequivalence of ONS-3010 (Humira biosimilar) and the US and European originator versions of Humira (adalimumab). The data was presented at the 2016 American College of Rheumatology Annual Scientific Meeting in Washington, DC on November 13, 2016.

Click here to read the full release